ClinicalTrials.gg
CompletedNCT05564676Updated Oct 4, 2022

Flaxseed Oil and Pomegranate Extract on Inflammation, Lipid Profile and Nutritional Status of Hemodialysis Patients

An interventional study of flaxseed oil and pomegranate dry extract and sunflower oil and microcrystalline cellulose in Chronic Kidney Diseases, Dialysis; Complications and Inflammation, sponsored by Santa Catarina Federal University. Completed at 1 site in Brazil. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-10-04.

Sponsored by Santa Catarina Federal University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled May 2021, registered Sep 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Renal Insufficiency, Chronic with a site in Brazil — 23 open to participants now, 39 under way, 15 of them phase 3. Renal Insufficiency, Chronic · Brazil.

Enrollment
81st of 123
50 · median 100
Started
2021
with 10 others
No phase
52 of 134
8 open now
Registered
95th of 134
by date

Among the 134 studies in Renal Insufficiency, Chronic with a site in Brazil, this one is the 81st largest by enrollment of the 123 interventional ones that give a count, is one of 11 that started in 2021, is one of 52 with no phase, and was the 95th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

23 of the 134 studies in Renal Insufficiency, Chronic with a site in Brazil are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Renal Insufficiency, Chronic with a site in Brazil, or all of them as a file.
02

Study summary

Nutritional and metabolic alterations in patients with chronic kidney disease (CKD) such as inflammation, oxidative stress, dyslipidemia, and poor nutritional status which associate with poor clinical outcome can potentially be targeted and ameliorated by interventions using nutritional supplements. The investigators evaluated the effects of 8 weeks of oral supplementation with flaxseed oil and pomegranate dry extract on markers of inflammation, lipid profile and nutritional status of individuals undergoing hemodialysis (HD).

The goal of this randomized, placebo-controlled, double-blind clinical trial is to evaluate the effects of 8 weeks of oral supplementation with flaxseed oil and pomegranate dry extract on markers of inflammation, lipid profile and nutritional status of individuals undergoing hemodialysis (HD).

Participants will be randomly assigned, in a 1:1 ratio, to supplementation group to receive twice a day 1 capsule of 1.000 mg of flaxseed oil plus 1 capsule of 600mg of pomegranate dry extract; or to placebo group, to receive twice a day 1 capsule of 1.000 mg of sunflower oil plus 1 capsule of 600mg of microcrystalline celulose.

03

Conditions studied

  • Chronic Kidney Diseases
  • Dialysis; Complications
  • Inflammation
  • Lipid Metabolism Disorders

Keywords

  • Chronic kidney disease
  • hemodialysis
  • inflammation
  • dyslipidemia
  • flaxseed
  • pomagranate
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥ 19 years; have a diagnosis of CKD;
  • perform HD three times a week for a period of ≥ three months;
  • acceptance of participation.

Exclusion criteria

Exclusion Criteria:

  • history of allergy to flaxseed or pomegranate;
  • infection or hospitalization in the beginning or during the course of the study;
  • seropositivity and active ;
  • pregnancy or breastfeeding.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    flaxseed oil and pomegranate extract

    2g daily of flaxseed oil plus 1.2g daily pomegranate dry extract

    Dietary Supplement: flaxseed oil and pomegranate dry extract

  • Placebo comparator
    sunflower oil and microcrystalline cellulose

    2g daily of sunflower oil plus 1.2g daily microcrystalline cellulose

    Dietary Supplement: sunflower oil and microcrystalline cellulose

Interventions

  • Dietary supplementflaxseed oil and pomegranate dry extract

    The flaxseed oil were yellow capsules with 1.0 g each and the pomegranate dry extract capsules were green with 0.6 g each.

  • Dietary supplementsunflower oil and microcrystalline cellulose

    The sunflower oil were yellow capsules with 1.0 g each and the microcrystalline cellulose capsules were green with 0.6 g each.

06

What researchers measure

Primary outcomes

  1. interleukin 2

    Time frame: Change from Baseline and at 8 weeks (end of study)

  2. interleukin 4

    Time frame: Change from Baseline and at 8 weeks (end of study)

  3. interleukin 6

    Time frame: Change from Baseline and at 8 weeks (end of study)

  4. interleukin 10

    Time frame: Change from Baseline and at 8 weeks (end of study)

  5. tumor necrosis factor alpha

    Time frame: Change from Baseline and at 8 weeks (end of study)

  6. interferon-gamma

    Time frame: Change from Baseline and at 8 weeks (end of study)

  7. C-reactive protein

    Time frame: Change from Baseline and at 8 weeks (end of study)

Secondary outcomes

  1. total cholesterol

    Time frame: Change from Baseline and at 8 weeks (end of study)

  2. high-density lipoprotein

    Time frame: Change from Baseline and at 8 weeks (end of study)

  3. low-density lipoprotein

    Time frame: Change from Baseline and at 8 weeks (end of study)

  4. triglycerides

    Time frame: Change from Baseline and at 8 weeks (end of study)

Other outcomes

  1. weight

    Time frame: Change from Baseline and at 8 weeks (end of study)

  2. height

    Time frame: Change from Baseline and at 8 weeks (end of study)

  3. handgrip strength

    Time frame: Change from Baseline and at 8 weeks (end of study)

  4. waist circumference

    Time frame: Change from Baseline and at 8 weeks (end of study)

  5. calf circumference

    Time frame: Change from Baseline and at 8 weeks (end of study)

07

Study locations

1 site
  • Federal University of Santa Catarina
    Florianópolis, Santa Catarina 88040400, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jul 2021, 2 months.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's 2 months is below that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2022
First posted
Oct 3, 2022
StartActual
May 1, 2021
Primary completionActual
Jul 31, 2021
CompletionActual
Jul 31, 2021
Last update
Oct 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05564676
Lead sponsor
Santa Catarina Federal University
Responsible party
Aline Miroski de Abreu (Principal investigator, Santa Catarina Federal University) — Principal investigator
First posted
Oct 3, 2022
Start date
May 1, 2021
Primary completion
Jul 31, 2021
Completion
Jul 31, 2021
Last update
Oct 4, 2022

Study contacts

Aline M de Abreu, MSc
principal investigator · UFSC

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion